Dendritic cell-derived exosomes for cancer therapy

Jonathan M. Pitt, Fabrice André, Sebastian Amigorena, Jean Charles Soria, Alexander Eggermont, Guido Kroemer, Laurence Zitvogel

Onderzoeksoutput: Bijdrage aan tijdschriftArtikel recenserenpeer review

415 Citaten (Scopus)

Samenvatting

DC-derived exosomes (Dex) are nanometer-sized membrane vesicles that are secreted by the sentinel antigen-presenting cells of the immune system: DCs. Like DCs, the molecular composition of Dex includes surface expression of functional MHC-peptide complexes, costimulatory molecules, and other components that interact with immune cells. Dex have the potential to facilitate immune cell-dependent tumor rejection and have distinct advantages over cell-based immunotherapies involving DCs. Accordingly, Dex-based phase I and II clinical trials have been conducted in advanced malignancies, showing the feasibility and safety of the approach, as well as the propensity of these nanovesicles to mediate T and NK cell-based immune responses in patients. This Review will evaluate the interactions of Dex with immune cells, their clinical progress, and the future of Dex immunotherapy for cancer.

Originele taal-2Engels
Pagina's (van-tot)1224-1232
Aantal pagina's9
TijdschriftJournal of Clinical Investigation
Volume126
Nummer van het tijdschrift4
DOI's
StatusGepubliceerd - 1 apr. 2016
Extern gepubliceerdJa

Vingerafdruk

Duik in de onderzoeksthema's van 'Dendritic cell-derived exosomes for cancer therapy'. Samen vormen ze een unieke vingerafdruk.

Citeer dit